BRPI0407583A - solução oftálmica lìmpida e estável - Google Patents

solução oftálmica lìmpida e estável

Info

Publication number
BRPI0407583A
BRPI0407583A BRPI0407583-8A BRPI0407583A BRPI0407583A BR PI0407583 A BRPI0407583 A BR PI0407583A BR PI0407583 A BRPI0407583 A BR PI0407583A BR PI0407583 A BRPI0407583 A BR PI0407583A
Authority
BR
Brazil
Prior art keywords
stable ophthalmic
ophthalmic solution
clearly
stable
quinolone
Prior art date
Application number
BRPI0407583-8A
Other languages
English (en)
Inventor
Nitin Laddha
Bhowmick Ritu
Laddha Balaram
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BRPI0407583A publication Critical patent/BRPI0407583A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"SOLUçãO OFTáLMICA LìMPIDA E ESTáVEL". Onde oferece uma composição oftálmica límpida e estável compreendendo (a) uma quinolona ou um aminoglicosídeo, (b) um corticosteróide, (c) uma ciclodextrina e (d) outros excipientes farmaceuticamente aceitáveis em um veículo líquido.
BRPI0407583-8A 2003-02-21 2004-02-23 solução oftálmica lìmpida e estável BRPI0407583A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN212MU2003 2003-02-21
PCT/IN2004/000048 WO2004087043A2 (en) 2003-02-21 2004-02-23 Stable ophthalmic formulation containing an antibiotic and a corticosteroid

Publications (1)

Publication Number Publication Date
BRPI0407583A true BRPI0407583A (pt) 2006-02-14

Family

ID=33104995

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0407583-8A BRPI0407583A (pt) 2003-02-21 2004-02-23 solução oftálmica lìmpida e estável

Country Status (8)

Country Link
US (1) US20070148192A1 (pt)
EP (1) EP1596823A2 (pt)
JP (1) JP2006518769A (pt)
KR (1) KR20050105477A (pt)
BR (1) BRPI0407583A (pt)
CA (1) CA2516429A1 (pt)
MX (1) MXPA05008913A (pt)
WO (1) WO2004087043A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310590A (en) * 1993-02-04 1994-05-10 Minnesota Mining And Manufacturing Company Stitchbonded articles
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1706095B1 (en) 2004-01-20 2008-12-24 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
CA2615360A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
WO2007099431A2 (en) * 2006-02-28 2007-09-07 Wockhardt Ltd An aqueous liquid pharmaceutical compositions of gatifloxacin
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
AU2016253668B2 (en) * 2006-03-14 2018-12-06 Cls Pharmaceuticals, Inc. Ophthalmic compositions comprising povidone-iodine
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
WO2008002117A1 (es) * 2006-06-27 2008-01-03 Jimenez Bayardo, Arturo Solución oftálmica de ciprofloxacina y dexametasona
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
EP2173169B1 (en) * 2007-06-28 2014-05-21 CyDex Pharmaceuticals, Inc. Nasal delivery of aqueous corticosteroid solutions
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
EP2249921B1 (en) * 2008-02-25 2020-06-17 Eyegate Pharmaceuticals, Inc. Enhanced delivery of dexamethasone phosphate to ocular tissues through iontophoresis
EP2309980A1 (en) * 2008-07-08 2011-04-20 S.I.F.I. Societa' Industria Farmaceutica Italiana Ophthalmic compositions for treating pathologies of the posterior segment of the eye
EP2502616A1 (fr) * 2011-03-21 2012-09-26 Matthew Krayenbuhl Composition pharmaceutique nasale
KR101304341B1 (ko) * 2011-09-19 2013-09-11 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6694525B2 (ja) * 2016-05-06 2020-05-13 ハーロウ・ヘルス・インコーポレイテッドＨａｒｒｏｗ Ｈｅａｌｔｈ， Ｉｎｃ． 薬学的眼病用組成物およびそれを製造するための方法
JP7138103B2 (ja) * 2016-11-29 2022-09-15 オキュリス エスエー 眼科用活性医薬成分送達のためのシクロデキストリン固体複合体の製造
JP7607935B2 (ja) 2019-01-03 2025-01-06 サイクラリティ・セラピューティクス・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
EP4670738A3 (en) 2019-07-01 2026-03-04 Oculis Operations Sàrl Method for stabilizing the ph of an aqueous composition comprising a drug
CA3169544A1 (en) * 2020-03-02 2021-09-10 Pablo Aviles Marin Compounds for use in inflammatory conditions
US20230233572A1 (en) * 2020-06-11 2023-07-27 Sentiss Pharma Private Limited Ophthalmic compositions comprising a combination of fluoroquinolone antibacterial agent and an anti-inflammatory agent
CN116531319A (zh) * 2023-05-24 2023-08-04 德阳市人民医院 一种眼用抗菌凝胶及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3704907A1 (de) * 1987-02-17 1988-08-25 Bayer Ag Topisch anwendbare zubereitungen von gyrase-inhibitoren in kombination mit kortikosteroiden
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
WO2001022936A1 (en) * 1999-09-24 2001-04-05 Alcon Universal Ltd. Topical suspension formulations containing ciprofloxacin and dexamethasone
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
CA2428189A1 (en) * 2000-11-15 2002-05-23 Mainde Chandrashekhar Pharmaceutival preparations comprising corticosteroids and antiinfective agents

Also Published As

Publication number Publication date
JP2006518769A (ja) 2006-08-17
US20070148192A1 (en) 2007-06-28
CA2516429A1 (en) 2004-10-14
MXPA05008913A (es) 2005-10-05
KR20050105477A (ko) 2005-11-04
EP1596823A2 (en) 2005-11-23
WO2004087043A2 (en) 2004-10-14
WO2004087043B1 (en) 2005-01-27
WO2004087043A3 (en) 2004-12-16

Similar Documents

Publication Publication Date Title
BRPI0407583A (pt) solução oftálmica lìmpida e estável
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
TR200100054T2 (tr) Paroksetin metansülfonat
EE200300236A (et) 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
FR13C0062I2 (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
ATE460942T1 (de) Exendine zur glucagon suppression
TW200716157A (en) Pharmaceutical formulations and methods of treatment using the same
EA200800337A1 (ru) Композиция и способ введения офтальмологически активных средств
PY0401585A (es) Formulaciones farmaceuticas liquidas de palonosetron
DE69940635D1 (de) Copolymer-zusammensetzungen zur oralen verabreichung
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
PT1228028E (pt) Sais de hidroxieicosatetraeniato, composicoes e metodos para utilizacao no tratamento de perturbacoes da secura ocular
MA27998A1 (fr) Nouvelle formulation
NO20040702L (no) Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
EE05415B1 (et) Ravimi manustamise vahend, eriti androgeenide manustamiseks
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
DK1220852T3 (da) Substituerede diazepaner
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
NO20063393L (no) Farmasoytiske preparater
DK1377316T3 (da) Farmaceutisk sammensætning på grundlag af azalider til lokal anvendelse i oftalmologien

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.